News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Angela Mae Obermiller, PharmD

Articles by Angela Mae Obermiller, PharmD

The Longstanding Quest for a Better Endocrine Therapy Continues High-Dose Fulvestrant: Have We Found Its Effective Dose, Combination, Setting, or Sequence?

ByAngela Mae Obermiller, PharmD,Mehmet Sitki Copur, MD

March 15th 2011

Although several endocrine therapies are available today, the authors of this commentary contend that the quest for a better tamoxifen is ongoing.

Latest Updated Articles

The Longstanding Quest for a Better Endocrine Therapy Continues High-Dose Fulvestrant: Have We Found Its Effective Dose, Combination, Setting, or Sequence?
March 15th 2011

Trending on OncLive

In Vivo CD19/CD20 CAR T-Cell Therapy Is Safe, Yields 100% ORR at Phase 1, Dose Level 2 in R/R Non-Hodgkin Lymphomas

Pumitamig Plus Chemo Demonstrates Encouraging Efficacy in Frontline NSCLC

Experts Weigh In on Some of the Most Impactful Data in Melanoma From ASCO 2026

Emiltatug Ledadotin Elicits Responses in Aggressive Adenoid Cystic Carcinoma

A global, randomized, double-blinded, Phase 3 trial of vorasidenib vs placebo in patients with grade 2 glioma with an IDH1/2 mutation (INDIGO): updated efficacy and safety